$CRCW
Crypto Co Stock $crcw

$crcw Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000149315223018535 Filed on May 22, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022 Q1
Revenue	$156.9K	$103.8K	$142.5K
YoY Change	10.09%	-51.55%	10079.29%
Cost Of Revenue	$97.87K	$103.0K	$79.22K
YoY Change	23.54%	-62.37%
Gross Profit	$59.02K	$750.00	$63.29K
YoY Change	-6.74%	-101.26%	4420.71%
Gross Profit Margin	37.62%	0.72%	44.41%
Selling, General & Admin	$817.6K	$588.6K	$1.517M
YoY Change	-46.1%	-15.68%	476.22%
% of Gross Profit	1385.22%	78482.67%	2396.67%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$0.00	$21.74K	$21.74K
YoY Change	-100.0%	117.18%
% of Gross Profit	0.0%	2898.67%	34.35%
Operating Expenses	$828.4K	$610.4K	$1.539M
YoY Change	-46.16%	-13.8%	484.46%
Operating Profit	-$769.4K	-$609.6K	-$1.475M
YoY Change	-47.85%	-20.59%	463.41%
Interest Expense	$1.971M	-$85.57K	-$1.024M
YoY Change	-292.49%	1932.54%	26703.14%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$142.7K	$15.00K
YoY Change	-100.0%	-165.32%	-90.67%
Pretax Income	-$2.771M	-$837.9K	-$2.484M
YoY Change	11.56%	51.41%	2269.04%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$2.771M	-$837.9K	-$2.484M
YoY Change	11.56%	51.41%	2269.04%
Net Earnings / Revenue	-1766.38%	-807.46%	-1743.16%
Basic Earnings Per Share	-$0.11		-$0.11
Diluted Earnings Per Share	-$0.11	-$0.04	-$110.4K
COMMON SHARES
Basic Shares Outstanding	25.10M shares	24.55M shares	22.50M shares
Diluted Shares Outstanding	25.10M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.68K	$110.6K	$98.80K
YoY Change	-83.12%	46.12%	-88.32%
Cash & Equivalents	$16.68K	$110.6K	$98.80K
Short-Term Investments
Other Short-Term Assets	$57.72K	$81.32K	$1.082M
YoY Change	-94.66%	-5.64%
Inventory
Prepaid Expenses	$57.72K	$81.32K
Receivables
Other Receivables
Total Short-Term Assets	$74.39K	$191.9K	$1.180M
YoY Change	-93.7%	18.56%	39.34%
LONG-TERM ASSETS
Property, Plant & Equipment		$50.00K
YoY Change
Goodwill	$740.5K	$740.5K
YoY Change		0.0%
Intangibles		$574.2K
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$50.00K
YoY Change
Total Long-Term Assets	$1.304M	$1.365M	$1.347M
YoY Change	-3.22%	0.49%
TOTAL ASSETS
Total Short-Term Assets	$74.39K	$191.9K	$1.180M
Total Long-Term Assets	$1.304M	$1.365M	$1.347M
Total Assets	$1.378M	$1.557M	$2.528M
YoY Change	-45.47%	2.42%	198.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.458M	$2.266M	$2.000M
YoY Change	22.92%	17.16%	4.19%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.361M	$2.211M	$1.980M
YoY Change	19.28%	397.49%	559.88%
Total Short-Term Liabilities	$4.879M	$4.477M	$3.979M
YoY Change	22.61%	88.24%	79.31%
LONG-TERM LIABILITIES
Long-Term Debt	$138.9K	$139.1K	$157.4K
YoY Change	-11.76%	-11.61%	-25.37%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$138.9K	$139.1K	$157.4K
YoY Change	-11.76%	-11.61%	-25.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.879M	$4.477M	$3.979M
Total Long-Term Liabilities	$138.9K	$139.1K	$157.4K
Total Liabilities	$5.018M	$4.616M	$4.137M
YoY Change	21.31%	82.04%	70.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$42.30M	-$39.53M
YoY Change		16.72%
Common Stock	$38.66M	$36.47M
YoY Change		11.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.640M	-$3.059M	-$1.609M
YoY Change
Total Liabilities & Shareholders Equity	$1.378M	$1.557M	$2.528M
YoY Change	-45.47%	2.42%	198.36%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022 Q1
OPERATING ACTIVITIES
Net Income	-$2.771M	-$837.9K	-$2.484M
YoY Change	11.56%	51.41%	2269.04%
Depreciation, Depletion And Amortization	$0.00	$21.74K	$21.74K
YoY Change	-100.0%	117.18%
Cash From Operating Activities	-$287.6K	-$854.7K	-$504.8K
YoY Change	-43.03%	32.11%	2017.32%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$983.5K	-$1.034M
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities		$983.5K	-$1.034M
YoY Change		74.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$25.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$193.6K	-104.2K	1.561M
YoY Change	-87.6%	1795.09%	85.16%
NET CHANGE
Cash From Operating Activities	-$287.6K	-854.7K	-504.8K
Cash From Investing Activities		983.5K	-1.034M
Cash From Financing Activities	$193.6K	-104.2K	1.561M
Net Change In Cash	-$93.93K	24.55K	23.10K
YoY Change	-506.62%	-127.53%
FREE CASH FLOW
Cash From Operating Activities	-$287.6K	-$854.7K	-$504.8K
Capital Expenditures	$0.00	-$983.5K	-$1.034M
Free Cash Flow	-$287.6K	$128.8K	$528.7K
YoY Change	-154.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001688126
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2023Q1	us-gaap	Depreciation Depreciation		usd
CY2023Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2022Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2022Q1	CRCW	Loss On Disposal Of Business LossOnDisposalOfBusiness		usd
CY2023Q1	CRCW	Other Income Recovery Of Token Investment OtherIncomeRecoveryOfTokenInvestment		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2023Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-55726
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	THE CRYPTO COMPANY
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-4212105
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	23823 Malibu Road
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	# 50477
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Malibu
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90265
CY2023Q1	dei	City Area Code CityAreaCode	(424)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	228-9955
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30402320	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16677	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110606	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	57717	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	81317	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	74394	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	191923	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	740469	usd
CY2022Q4	us-gaap	Goodwill Goodwill	740469	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	563336	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	574169	usd
CY2023Q1	us-gaap	Assets Assets	1378199	usd
CY2022Q4	us-gaap	Assets Assets	1556561	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2457771	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2265548	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	60000	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	2361218	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2211353	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4878989	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4476901	usd
CY2023Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	125000	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	125000	usd
CY2023Q1	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	13864	usd
CY2022Q4	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	14100	usd
CY2023Q1	us-gaap	Liabilities Liabilities	5017853	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4616001	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25740537	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25740537	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23950380	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23950380	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	25741	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	23950	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	38637372	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	36448046	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-42302767	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39531436	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3639654	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3059440	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1378199	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1556561	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	156893	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	142512	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	97868	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	79218	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	59024	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	63294	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	431049	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	631390	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10833	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10833	usd
CY2022Q1	us-gaap	Depreciation Depreciation	10903	usd
CY2023Q1	CRCW	Sharebased Compensation Employee SharebasedCompensationEmployee	6761	usd
CY2022Q1	CRCW	Sharebased Compensation Employee SharebasedCompensationEmployee	163000	usd
CY2023Q1	CRCW	Sharebased Compensation Nonemployee SharebasedCompensationNonemployee	379799	usd
CY2022Q1	CRCW	Sharebased Compensation Nonemployee SharebasedCompensationNonemployee	722461	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	828442	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	1538587	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-769418	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1475293	usd
CY2023Q1	CRCW	Loss On Disposal Of Business LossOnDisposalOfBusiness	31000	usd
CY2022Q1	CRCW	Other Income Recovery Of Token Investment OtherIncomeRecoveryOfTokenInvestment	15000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1970913	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	1023883	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2771331	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2484176	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2771331	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2484176	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25097908	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22502177	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1015815	usd
CY2022Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	3.28
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	26240	usd
CY2022Q1	CRCW	Stock Compensation Expense In Connection With Issuance Of Common Stock StockCompensationExpenseInConnectionWithIssuanceOfCommonStock	885461	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	979304	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2484176	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-1608987	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3059440	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3059440	usd
CY2023Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5.00
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25000	usd
CY2023Q1	CRCW	Stock Compensation Expense In Connection With Issuance Of Common Stock StockCompensationExpenseInConnectionWithIssuanceOfCommonStock	386560	usd
CY2023Q1	CRCW	Adjustments To Additional Paid In Capital Debt Discount For Warrants AdjustmentsToAdditionalPaidInCapitalDebtDiscountForWarrants	1779557	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2771331	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3639654	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3639654	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2771331	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2484176	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10833	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	21736	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	386560	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	885461	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1779557	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	979304	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-31000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-23600	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-27157	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	192224	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	65749	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	60000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-287557	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-504769	usd
CY2022Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1033500	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1033500	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	159122	usd
CY2023Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	327750	usd
CY2022Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1535125	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	26241	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	193628	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1561366	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-93929	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23097	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	110606	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	75699	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16677	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	98796	usd
CY2023Q1	us-gaap	Cash Cash	16677	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2771331	usd
CY2023Q1	CRCW	Working Capital WorkingCapital	4804595	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-42302767	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zDNwCSx1sK5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_862_zZy6xMEv54tc">Use of estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of these consolidated financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s significant estimates and assumptions include but are not limited to the valuation allowances of deferred taxes, and share-based compensation expenses. Actual results may differ from these estimates. In addition, any change in these estimates or their related assumptions could have an adverse effect on the Company’s operating results.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	650000	usd
CY2023Q1	us-gaap	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Intangibles BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles	54166	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10833	usd
CY2023Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	125000	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	125000	usd
CY2023Q2	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	17916.94	usd
CY2023Q2	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	2083.06	usd
CY2023Q2	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	15000	usd
CY2023Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	1.50	pure
CY2023Q1	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.60	pure
CY2023Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	1.50	pure
CY2023Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	1349457	usd
CY2023Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	740469	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2281429	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.26
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y3M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5155003	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2281429	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.26
CY2023Q1	CRCW	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P3Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5155003	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2281429	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.26
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5155003	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	0	usd
CY2022Q1	us-gaap	Payments For Rent PaymentsForRent	0	usd

Files In Submission

Name	View Source	Status
crcw-20230331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-018535-index-headers.html	Edgar Link	pending
0001493152-23-018535-index.html	Edgar Link	pending
0001493152-23-018535.txt	Edgar Link	pending
0001493152-23-018535-xbrl.zip	Edgar Link	pending
crcw-20230331.xsd	Edgar Link	pending
ex10-41.htm	Edgar Link	pending
ex10-41_001.jpg	Edgar Link	pending
ex10-41_002.jpg	Edgar Link	pending
ex10-41_003.jpg	Edgar Link	pending
ex10-42.htm	Edgar Link	pending
ex10-42_001.jpg	Edgar Link	pending
ex10-42_002.jpg	Edgar Link	pending
ex10-42_003.jpg	Edgar Link	pending
ex10-42_004.jpg	Edgar Link	pending
ex10-42_005.jpg	Edgar Link	pending
ex10-42_006.jpg	Edgar Link	pending
ex10-42_007.jpg	Edgar Link	pending
ex10-42_008.jpg	Edgar Link	pending
ex10-42_009.jpg	Edgar Link	pending
ex10-42_010.jpg	Edgar Link	pending
ex10-42_011.jpg	Edgar Link	pending
ex10-42_012.jpg	Edgar Link	pending
ex10-42_013.jpg	Edgar Link	pending
ex10-42_014.jpg	Edgar Link	pending
ex10-42_015.jpg	Edgar Link	pending
ex10-42_016.jpg	Edgar Link	pending
ex10-42_017.jpg	Edgar Link	pending
ex10-42_018.jpg	Edgar Link	pending
ex10-42_019.jpg	Edgar Link	pending
ex10-43.htm	Edgar Link	pending
ex10-43_001.jpg	Edgar Link	pending
ex10-43_002.jpg	Edgar Link	pending
crcw-20230331_def.xml	Edgar Link	unprocessable
crcw-20230331_lab.xml	Edgar Link	unprocessable
crcw-20230331_pre.xml	Edgar Link	unprocessable
ex10-43_003.jpg	Edgar Link	pending
ex10-43_004.jpg	Edgar Link	pending
ex10-43_005.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRCW
Crypto Co Stock $crcw

2023 Q1 Form 10-Q Financial Statement

#000149315223018535 Filed on May 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRCW Crypto Co Stock $crcw

2023 Q1 Form 10-Q Financial Statement

#000149315223018535 Filed on May 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRCW
Crypto Co Stock $crcw